

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Appln. N Confirmation U.S. Filing D Title of Inven	of : Cordingley, Michael G. No. : 10/736,301 No. : 5463 ate : December 15, 2003 ation : Method for Improving the I t No.: 9/270A) Art Unit:) Examiner: Pharmacokinetics	1614 To be assigned of an NNRTI
Commissione P. O. Box 145 Alexandria, V			
April 26, 200	4		
2 nd TRANS	MITTAL LETTER FOR INFO	RMATION DISC	CLOSURE STATEMENT
Sir:			
	nerewith concerning the subject apport 1449A/B) under 37 C.F.R. §§1		
date of a nation §1.53 (d); ii) §37 C.F.R. §1.0 on the merits;	o). This Statement is being from a application other than a continuithin three (3) months of the date 491 in an international application or iv) before the mailing of a first amination under 37 C.F.R. §1.114.	nued prosecution a of entry of the na ; iii) before the m Office action after	ntional stage as set forth in ailing of a first Office action
notice of allow	This Statement is being figh), but before the mailing date of: wance under 37 C.F.R. §1.311, or ition. This Statement is being acco	i) a final action uniii) an action that	nder 37 C.F.R. §1.113, ii) a
	A statement as specified in 37 C	.F.R. §1.97(e) [se	e below]; or
	The fee set forth in 37 C.F.R. §1.	.17(p).	
	The Commissioner is here \$180.00 fee set forth in 37 C.F.R	•	

	ent as sp	This Statement is being filed after the period specified in 37 C.F.R. or before payment of the issue fee. This Statement is accompanied by a ecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)	
	stateme	Each item of information contained in the instant information disclosure nt was first cited in any communication from a foreign patent office in a part foreign application not more than three (3) months prior to the filing of ant information disclosure statement; or
	stateme foreign making informa §1.56(c	No item of information contained in the instant information disclosure nt was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after reasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 C.F.R.) more than three (3) months prior to the filing of the instant information are statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap _l	Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a edication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying sclosure statement.
	quired u	mmissioner is hereby authorized to charge payment of any additional filing nder 37 C.F.R. §1.16 and any patent application processing fees under 37 or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368

Ridgefield, CT 06877 Tel: (203) 798-4868 I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Certificate of Mailing

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

On April 26, 2004

Alan R. Stempel, Reg. No

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Complete if Known				
Application Number	10/736,301			
Filing Date	December 15, 2003			
First Named Inventor	Cordingley, Michael G.			
Art Unit	1614			
Examiner Name	To be assigned			
Attorney Docket Number	9/270A			

(Use as many sheets as necessary)

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,391,919 B1	05/21/2002	Robert F. Kaltenbach et al	
		US-			
		US-			
	*************	US-			
4.0° 10° 10° 10° 10° 10° 10° 10° 10° 10° 1	~^~	US-	-		
		US-			
		US-			
	***************************************	US-			
		US-			
4. **** ********************************		US-			
		US-			
***************************************		US-	,,,		AND THE PROPERTY OF THE PROPER
		US-			
		US-	***		
	•	US-	~		
	***************************************	US-			
***************************************	······	US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ (<i>Number</i> ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T€	
		WO 98/44913	10/15/1998	Triangle Pharmaceuticals, Ir			
	ļ	WO 01/96338 A1	12/20/2001	BI (Canada) LTD.			
					,		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/736,301	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			SURE	Filing Date	December 15, 2003	
			CANT	First Named Inventor	Cordingley, Michael G.	
				Art Unit	1614	
(Use as many sheets as necessary))	Examiner Name	To be assigned	
Sheet	2	of	2	Attorney Docket Number	9/270A	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LISA I. MALATY ET AL; Drug Interactions of HIV Protease Inhibitors; Drug Safety Feb. 1999 Vol. 20 No. 2 pages 147-169; Adis International Limited	
	•••••••	Copy of International Search Report Reference No. PCT/EP 03/14224	
	••••••		
	•••••••		
	•••••		
	•••••		
	***************************************		ļ
	•••••		
Examiner		Date	

Considered Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.